{"pmid":32416433,"title":"Metronomic oral vinorelbine and lung cancer therapy during the COVID 19 pandemic: A single-center experience.","text":["Metronomic oral vinorelbine and lung cancer therapy during the COVID 19 pandemic: A single-center experience.","COVID 19 pandemic is a worldwide health emergency. Every single Hospital and Department was forced to radically modify clinical practice decreasing or stopping daily activities. Oncological patients had to carry on treatments in order to prevent disease progression and improve their quality of life. However, many health workers may be a potential source of infection if not tested with swabs but this diagnostic procedure was not suitable universally in Italy. Aiming to reduce hospitalization of our patients with advanced lung cancer, vinorelbine in its metronomic formulation is one of the best strategy. Here, we report the experience with oral vinorelbine in a few patients of our Oncology Department.","Lung Cancer","Rossi, David","32416433"],"abstract":["COVID 19 pandemic is a worldwide health emergency. Every single Hospital and Department was forced to radically modify clinical practice decreasing or stopping daily activities. Oncological patients had to carry on treatments in order to prevent disease progression and improve their quality of life. However, many health workers may be a potential source of infection if not tested with swabs but this diagnostic procedure was not suitable universally in Italy. Aiming to reduce hospitalization of our patients with advanced lung cancer, vinorelbine in its metronomic formulation is one of the best strategy. Here, we report the experience with oral vinorelbine in a few patients of our Oncology Department."],"journal":"Lung Cancer","authors":["Rossi, David"],"date":"2020-05-17T11:00:00Z","year":2020,"_id":"32416433","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.lungcan.2020.05.001","keywords":["lung cancer","oral","vinorelbine"],"locations":["Italy","vinorelbine"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Prevention"],"weight":1,"_version_":1666994545903009792,"score":9.490897,"similar":[{"pmid":32426292,"pmcid":"PMC7212352","title":"Oral Chemotherapy for Treatment of Lung Cancer.","text":["Oral Chemotherapy for Treatment of Lung Cancer.","The global COVID-19 pandemic has disrupted healthcare delivery, particularly for patients with advanced lung cancer. While certain aspects of care can be safely omitted or delayed, systemic therapy plays an important role in survival and quality of life for patients with advanced lung cancer; limiting access to systemic therapy will compromise cancer-related outcomes. This can be at odds with strategies to mitigate risk of COVID-19 exposure, which include reducing hospital and clinic visits. One important strategy is implementation of oral cancer therapies. Many standard regimens require intravenous infusions but there are specific circumstances where an oral agent could be an acceptable alternative. Integrating oral therapeutics can permit patients to receive effective systemic treatment without the exposure risks associated with frequent infusions. Here, we review currently available oral cytotoxic agents with a potential role in the treatment of lung cancer.","Front Oncol","Jonna, Sushma","Reuss, Joshua E","Kim, Chul","Liu, Stephen V","32426292"],"abstract":["The global COVID-19 pandemic has disrupted healthcare delivery, particularly for patients with advanced lung cancer. While certain aspects of care can be safely omitted or delayed, systemic therapy plays an important role in survival and quality of life for patients with advanced lung cancer; limiting access to systemic therapy will compromise cancer-related outcomes. This can be at odds with strategies to mitigate risk of COVID-19 exposure, which include reducing hospital and clinic visits. One important strategy is implementation of oral cancer therapies. Many standard regimens require intravenous infusions but there are specific circumstances where an oral agent could be an acceptable alternative. Integrating oral therapeutics can permit patients to receive effective systemic treatment without the exposure risks associated with frequent infusions. Here, we review currently available oral cytotoxic agents with a potential role in the treatment of lung cancer."],"journal":"Front Oncol","authors":["Jonna, Sushma","Reuss, Joshua E","Kim, Chul","Liu, Stephen V"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32426292","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.3389/fonc.2020.00793","keywords":["capecitabine","chemotherapy","etoposide","oral therapy","temozolomide","topotecan","vinorelbine"],"topics":["Prevention"],"weight":1,"_version_":1667252837948588033,"score":236.25719},{"pmid":32391282,"pmcid":"PMC7188943","title":"Results of Multilevel Containment Measures to Better Protect Lung Cancer Patients From COVID-19: The IEO Model.","text":["Results of Multilevel Containment Measures to Better Protect Lung Cancer Patients From COVID-19: The IEO Model.","A novel coronavirus causing severe acute respiratory syndrome (SARS), named SARS-CoV-2, was identified at the end of 2019. The spread of coronavirus disease 2019 (COVID-19) has progressively expanded from China, involving several countries throughout the world, leading to the classification of the disease as a pandemic by the World Health Organization (WHO). According to published reports, COVID-19 severity and mortality are higher in elderly patients and those with active comorbidities. In particular, lung cancer patients were reported to be at high risk of pulmonary complications related to SARS-CoV2 infection. Therefore, the management of cancer care during the COVID-19 pandemic is a crucial issue, to which national and international oncology organizations have replied with recommendations concerning patients receiving anticancer treatments, delaying follow-up visits and limiting caregiver admission to the hospitals. In this historical moment, medical oncologists are required to consider the possibility to delay active treatment administration based on a case-by-case risk/benefit evaluation. Potential risks associated with COVID-19 infection should be considered, considering tumor histology and natural course, disease setting, clinical conditions, and disease burden, together with the expected benefit, toxicities (e.g., myelosuppression or interstitial lung disease), and response obtained from the planned or ongoing treatment. In this study, we report the results of proactive measures including social media, telemedicine, and telephone triage for screening patients with lung cancer during the COVID-19 outbreak in the European Institute of Oncology (Milan, Italy). Proactive management and containment measures, applied in a structured and daily way, has significantly aided the identification of advance patients with suspected symptoms related to COVID-19, limiting their admission to our cancer center; we have thus been more able to protect other patients from possible contamination and at the same time guarantee to the suspected patients the immediate treatment and evaluation in referral hospitals for COVID-19.","Front Oncol","de Marinis, Filippo","Attili, Ilaria","Morganti, Stefania","Stati, Valeria","Spitaleri, Gianluca","Gianoncelli, Letizia","Del Signore, Ester","Catania, Chiara","Rampinelli, Cristiano","Omodeo Sale, Emanuela","Spaggiari, Lorenzo","Mastrilli, Fabrizio","Passaro, Antonio","32391282"],"abstract":["A novel coronavirus causing severe acute respiratory syndrome (SARS), named SARS-CoV-2, was identified at the end of 2019. The spread of coronavirus disease 2019 (COVID-19) has progressively expanded from China, involving several countries throughout the world, leading to the classification of the disease as a pandemic by the World Health Organization (WHO). According to published reports, COVID-19 severity and mortality are higher in elderly patients and those with active comorbidities. In particular, lung cancer patients were reported to be at high risk of pulmonary complications related to SARS-CoV2 infection. Therefore, the management of cancer care during the COVID-19 pandemic is a crucial issue, to which national and international oncology organizations have replied with recommendations concerning patients receiving anticancer treatments, delaying follow-up visits and limiting caregiver admission to the hospitals. In this historical moment, medical oncologists are required to consider the possibility to delay active treatment administration based on a case-by-case risk/benefit evaluation. Potential risks associated with COVID-19 infection should be considered, considering tumor histology and natural course, disease setting, clinical conditions, and disease burden, together with the expected benefit, toxicities (e.g., myelosuppression or interstitial lung disease), and response obtained from the planned or ongoing treatment. In this study, we report the results of proactive measures including social media, telemedicine, and telephone triage for screening patients with lung cancer during the COVID-19 outbreak in the European Institute of Oncology (Milan, Italy). Proactive management and containment measures, applied in a structured and daily way, has significantly aided the identification of advance patients with suspected symptoms related to COVID-19, limiting their admission to our cancer center; we have thus been more able to protect other patients from possible contamination and at the same time guarantee to the suspected patients the immediate treatment and evaluation in referral hospitals for COVID-19."],"journal":"Front Oncol","authors":["de Marinis, Filippo","Attili, Ilaria","Morganti, Stefania","Stati, Valeria","Spitaleri, Gianluca","Gianoncelli, Letizia","Del Signore, Ester","Catania, Chiara","Rampinelli, Cristiano","Omodeo Sale, Emanuela","Spaggiari, Lorenzo","Mastrilli, Fabrizio","Passaro, Antonio"],"date":"2020-05-12T11:00:00Z","year":2020,"_id":"32391282","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.3389/fonc.2020.00665","keywords":["covid-19","cancer","containment measures","coronavirus","lung cancer"],"locations":["China","Milan","Italy"],"countries":["China","Italy"],"countries_codes":["CHN|China","ITA|Italy"],"topics":["Prevention"],"weight":1,"_version_":1666528579979051008,"score":168.5372},{"pmid":32505076,"title":"Covid-19 and lung cancer: A greater fatality rate?","text":["Covid-19 and lung cancer: A greater fatality rate?","BACKGROUND: Currently there are no reported series determining the Covid-19 infected lung cancer patient s characteristics and outcome that allow us to clarify strategies to protect our patients. In our study we determine whether exists differences in cumulative incidence and severity of Covid-19 infection between lung cancer patients visiting our Medical Oncology department and the reference population of our center (320,000 people), in the current epicenter of the pandemic in Europe (Madrid, Spain). We also describe clinical and demographic factors associated with poor prognosis and Covid-19 treatment outcomes. PATIENTS AND METHODS: We retrospectively reviewed 1878 medical records of all Covid-19 patients who were admitted at Hospital Universitario Infanta Leonor of Madrid between March 5, 2020 and April 7, 2020, in order to detect cumulative incidence of Covid-19 in lung cancer patients. We also described Covid-19 treatment outcome, mortality and associated risk factors using univariate and multivariate logistic regression analysis. RESULTS: 17/1878 total diagnosis in our center had lung cancer (0.9 %) versus 1878/320,000 of the total reference population (p = 0.09). 9/17 lung cancer patients with Covid-19 diagnosis died (52.3 %) versus 192/1878 Covid-19 patients in our center (p < 0.0001). Dead lung cancer patients were elderly compared to survivors: 72 versus 64.5 years old (p = 0.12). Combined treatment with hydroxychloroquine and azithromycin improves the outcome of Covid-19 in lung cancer patients, detecting only 1/6 deaths between patients under this treatment versus others treatment, with statistical significance in the univariate and multivariate logistic regression (OR 0.04, p = 0.018). CONCLUSIONS: Lung cancer patients have a higher mortality rate than general population. Combined hydroxychloroquine and azithromycin treatment seems like a good treatment option. It is important to try to minimize visits to hospitals (without removing their active treatments) in order to decrease nosocomial transmission.","Lung Cancer","Rogado, Jacobo","Pangua, Cristina","Serrano-Montero, Gloria","Obispo, Berta","Marino, Almudena Martin","Perez-Perez, Mar","Lopez-Alfonso, Ana","Gullon, Pedro","Lara, Miguel Angel","32505076"],"abstract":["BACKGROUND: Currently there are no reported series determining the Covid-19 infected lung cancer patient s characteristics and outcome that allow us to clarify strategies to protect our patients. In our study we determine whether exists differences in cumulative incidence and severity of Covid-19 infection between lung cancer patients visiting our Medical Oncology department and the reference population of our center (320,000 people), in the current epicenter of the pandemic in Europe (Madrid, Spain). We also describe clinical and demographic factors associated with poor prognosis and Covid-19 treatment outcomes. PATIENTS AND METHODS: We retrospectively reviewed 1878 medical records of all Covid-19 patients who were admitted at Hospital Universitario Infanta Leonor of Madrid between March 5, 2020 and April 7, 2020, in order to detect cumulative incidence of Covid-19 in lung cancer patients. We also described Covid-19 treatment outcome, mortality and associated risk factors using univariate and multivariate logistic regression analysis. RESULTS: 17/1878 total diagnosis in our center had lung cancer (0.9 %) versus 1878/320,000 of the total reference population (p = 0.09). 9/17 lung cancer patients with Covid-19 diagnosis died (52.3 %) versus 192/1878 Covid-19 patients in our center (p < 0.0001). Dead lung cancer patients were elderly compared to survivors: 72 versus 64.5 years old (p = 0.12). Combined treatment with hydroxychloroquine and azithromycin improves the outcome of Covid-19 in lung cancer patients, detecting only 1/6 deaths between patients under this treatment versus others treatment, with statistical significance in the univariate and multivariate logistic regression (OR 0.04, p = 0.018). CONCLUSIONS: Lung cancer patients have a higher mortality rate than general population. Combined hydroxychloroquine and azithromycin treatment seems like a good treatment option. It is important to try to minimize visits to hospitals (without removing their active treatments) in order to decrease nosocomial transmission."],"journal":"Lung Cancer","authors":["Rogado, Jacobo","Pangua, Cristina","Serrano-Montero, Gloria","Obispo, Berta","Marino, Almudena Martin","Perez-Perez, Mar","Lopez-Alfonso, Ana","Gullon, Pedro","Lara, Miguel Angel"],"date":"2020-06-07T11:00:00Z","year":2020,"_id":"32505076","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.lungcan.2020.05.034","keywords":["covid-19","lung cancer","mortality","non-small cell lung cancer","small cell lung cancer"],"locations":["Madrid","Spain","Madrid"],"countries":["Spain"],"countries_codes":["ESP|Spain"],"topics":["Treatment"],"weight":1,"_version_":1668892488302067712,"score":154.1949},{"pmid":32342863,"title":"Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement.","text":["Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement.","BACKGROUND: The COVID-19 pandemic has caused radiotherapy resource pressures and led to increased risks for lung cancer patients and healthcare staff. An international group of experts in lung cancer radiotherapy established this practice recommendation pertaining to whether and how to adapt radiotherapy for lung cancer in the COVID-19 pandemic. METHODS: For this ESTRO & ASTRO endorsed project, 32 experts in lung cancer radiotherapy contributed to a modified Delphi consensus process. We assessed potential adaptations of radiotherapy in two pandemic scenarios. The first, an early pandemic scenario of risk mitigation, is characterized by an altered risk-benefit ratio of radiotherapy for lung cancer patients due to their increased susceptibility for severe COVID-19 infection, and minimization of patient travelling and exposure of radiotherapy staff. The second, a later pandemic scenario, is characterized by reduced radiotherapy resources requiring patient triage. Six common lung cancer cases were assessed for both scenarios: peripherally located stage I NSCLC, locally advanced NSCLC, postoperative radiotherapy after resection of pN2 NSCLC, thoracic radiotherapy and prophylactic cranial irradiation for limited stage SCLC and palliative thoracic radiotherapy for stage IV NSCLC. RESULTS: In a risk-mitigation pandemic scenario, efforts should be made not to compromise the prognosis of lung cancer patients by departing from guideline-recommended radiotherapy practice. In that same scenario, postponement or interruption of radiotherapy treatment of COVID-19 positive patients is generally recommended to avoid exposure of cancer patients and staff to an increased risk of COVID-19 infection. In a severe pandemic scenario characterized by reduced resources, if patients must be triaged, important factors for triage include potential for cure, relative benefit of radiation, life expectancy, and performance status. Case-specific consensus recommendations regarding multimodality treatment strategies and fractionation of radiotherapy are provided. CONCLUSION: This joint ESTRO-ASTRO practice recommendation established pragmatic and balanced consensus recommendations in common clinical scenarios of radiotherapy for lung cancer in order to address the challenges of the COVID-19 pandemic.","Radiother Oncol","Guckenberger, Matthias","Belka, Claus","Bezjak, Andrea","Bradley, Jeffrey","Daly, Megan E","DeRuysscher, Dirk","Dziadziuszko, Rafal","Faivre-Finn, Corinne","Flentje, Michael","Gore, Elizabeth","Higgins, Kristin A","Iyengar, Puneeth","Kavanagh, Brian D","Kumar, Sameera","Le Pechoux, Cecile","Lievens, Yolande","Lindberg, Karin","McDonald, Fiona","Ramella, Sara","Rengan, Ramesh","Ricardi, Umberto","Rimner, Andreas","Rodrigues, George B","Schild, Steven E","Senan, Suresh","Simone Ii, Charles B","Slotman, Ben J","Stuschke, Martin","Videtic, Greg","Widder, Joachim","Yom, Sue S","Palma, David","32342863"],"abstract":["BACKGROUND: The COVID-19 pandemic has caused radiotherapy resource pressures and led to increased risks for lung cancer patients and healthcare staff. An international group of experts in lung cancer radiotherapy established this practice recommendation pertaining to whether and how to adapt radiotherapy for lung cancer in the COVID-19 pandemic. METHODS: For this ESTRO & ASTRO endorsed project, 32 experts in lung cancer radiotherapy contributed to a modified Delphi consensus process. We assessed potential adaptations of radiotherapy in two pandemic scenarios. The first, an early pandemic scenario of risk mitigation, is characterized by an altered risk-benefit ratio of radiotherapy for lung cancer patients due to their increased susceptibility for severe COVID-19 infection, and minimization of patient travelling and exposure of radiotherapy staff. The second, a later pandemic scenario, is characterized by reduced radiotherapy resources requiring patient triage. Six common lung cancer cases were assessed for both scenarios: peripherally located stage I NSCLC, locally advanced NSCLC, postoperative radiotherapy after resection of pN2 NSCLC, thoracic radiotherapy and prophylactic cranial irradiation for limited stage SCLC and palliative thoracic radiotherapy for stage IV NSCLC. RESULTS: In a risk-mitigation pandemic scenario, efforts should be made not to compromise the prognosis of lung cancer patients by departing from guideline-recommended radiotherapy practice. In that same scenario, postponement or interruption of radiotherapy treatment of COVID-19 positive patients is generally recommended to avoid exposure of cancer patients and staff to an increased risk of COVID-19 infection. In a severe pandemic scenario characterized by reduced resources, if patients must be triaged, important factors for triage include potential for cure, relative benefit of radiation, life expectancy, and performance status. Case-specific consensus recommendations regarding multimodality treatment strategies and fractionation of radiotherapy are provided. CONCLUSION: This joint ESTRO-ASTRO practice recommendation established pragmatic and balanced consensus recommendations in common clinical scenarios of radiotherapy for lung cancer in order to address the challenges of the COVID-19 pandemic."],"journal":"Radiother Oncol","authors":["Guckenberger, Matthias","Belka, Claus","Bezjak, Andrea","Bradley, Jeffrey","Daly, Megan E","DeRuysscher, Dirk","Dziadziuszko, Rafal","Faivre-Finn, Corinne","Flentje, Michael","Gore, Elizabeth","Higgins, Kristin A","Iyengar, Puneeth","Kavanagh, Brian D","Kumar, Sameera","Le Pechoux, Cecile","Lievens, Yolande","Lindberg, Karin","McDonald, Fiona","Ramella, Sara","Rengan, Ramesh","Ricardi, Umberto","Rimner, Andreas","Rodrigues, George B","Schild, Steven E","Senan, Suresh","Simone Ii, Charles B","Slotman, Ben J","Stuschke, Martin","Videtic, Greg","Widder, Joachim","Yom, Sue S","Palma, David"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32342863","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.radonc.2020.04.001","keywords":["covid-19","lung cancer","non-small cell lung cancer","pandemic","radiotherapy","small cell lung cancer"],"locations":["thoracic","thoracic"],"topics":["Prevention"],"weight":1,"_version_":1666138495097241600,"score":146.17302},{"pmid":32307085,"pmcid":"PMC7194703","title":"Practitioners specialized in oral health and coronavirus disease 2019: Professional guidelines from the French society of stomatology, maxillofacial surgery and oral surgery, to form a common front against the infectious risk.","text":["Practitioners specialized in oral health and coronavirus disease 2019: Professional guidelines from the French society of stomatology, maxillofacial surgery and oral surgery, to form a common front against the infectious risk.","Medical as well as non-medical practitioners specialized in oral health are at high risk of infection with the Coronavirus-19 (Covid-19) because of the proximity with potentially infected biological fluids. This risk is permanent, especially during examination, care and transfer of patients. Regarding the pandemic progression of Covid-19, efficient protocols of prevention are urgently needed. Based on our experience and on the recently reported guidelines from the French National Agency for Public Health (ARS, March 5, 2020), the French Society of Hospital Hygiene (SFHH, March 4, 2020) and the Department of Infectious Risk Prevention of the Hospitals of Paris-Public Assistance (APHP, March 6, 2020), we provide several recommendations for practitioners specialized in oral health, to protect themselves from nosocomial infections, especially Covid-19.","J Stomatol Oral Maxillofac Surg","32307085"],"abstract":["Medical as well as non-medical practitioners specialized in oral health are at high risk of infection with the Coronavirus-19 (Covid-19) because of the proximity with potentially infected biological fluids. This risk is permanent, especially during examination, care and transfer of patients. Regarding the pandemic progression of Covid-19, efficient protocols of prevention are urgently needed. Based on our experience and on the recently reported guidelines from the French National Agency for Public Health (ARS, March 5, 2020), the French Society of Hospital Hygiene (SFHH, March 4, 2020) and the Department of Infectious Risk Prevention of the Hospitals of Paris-Public Assistance (APHP, March 6, 2020), we provide several recommendations for practitioners specialized in oral health, to protect themselves from nosocomial infections, especially Covid-19."],"journal":"J Stomatol Oral Maxillofac Surg","date":"2020-04-21T11:00:00Z","year":2020,"_id":"32307085","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.jormas.2020.03.011","keywords":["coronavirus","covid-19","guidelines","oral","recommendations","sars-cov-2"],"locations":["Paris","French"],"countries":["France"],"countries_codes":["FRA|France"],"topics":["Prevention"],"weight":1,"_version_":1666138491191296000,"score":142.68915}]}